Oxatrex (Ofloxacin)

Ofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for DNA replication and transcription. This inhibition prevents bacterial DNA from unwinding and replicating, leading to bacterial cell death and clearance of the infection.

The dose of Oxatrex is determined by the prescribing clinician based on the type and severity of the infection, patient age, weight, renal function and other clinical factors. Healthcare providers set the appropriate regimen and duration for each individual case.

Ofloxacin is classified as pregnancy category C in many regions, indicating that risk cannot be ruled out. It should only be used during pregnancy or lactation when the potential benefit justifies the potential risk, and after consultation with an obstetrician or pediatrician.

To place an order, submit an enquiry on the Oxatrex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oxatrex (ofloxacin) shares the same class mechanism as other fluoroquinolones such as ciprofloxacin and levofloxacin, offering broad‑spectrum activity against Gram‑negative and some Gram‑positive bacteria. Ofloxacin’s pharmacokinetic profile provides good tissue penetration, making it suitable for urinary, respiratory and skin infections, while other agents may have different dosing frequencies or spectrum nuances.

Oxatrex tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Oxatrex is supplied as oral tablets that are taken by mouth with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with an adequate amount of water and not crushed or chewed unless specifically instructed.

Serious risks include tendon rupture, especially of the Achilles tendon, QT‑interval prolongation that can lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, peripheral neuropathy and Clostridioides difficile‑associated colitis. Patients should be advised to seek immediate medical attention if they experience any of these symptoms.

Oxatrex is contraindicated in individuals with a known hypersensitivity to ofloxacin or other fluoroquinolones, patients with a history of tendon disorders related to fluoroquinolone use, and those with a prolonged QT interval or significant cardiac arrhythmias. It should also be used with caution in pregnant or breastfeeding women and in patients with severe renal or hepatic impairment.